Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

Share Price is delayed by 15 minutes
Get Live Data
4,664.00    -214.00 (-4.39%)
Bid:
4,682.00
Ask:
4,686.00
Spread: 4.00 (0.085%)
Market Cap: £17.62b
HLMA Live PriceLast checked at - London Stock Exchange

Intraday Halma Share Chart

Acquisition

23 Jan 2013 09:00

RNS Number : 1738W
Halma PLC
23 January 2013
 



Halma plc ('Halma')

 

ACQUISITION OF BAODING LONGER PUMP

 

 

Halma, the leading safety, health and environmental technology group announces the completion on 23 January 2013 of the acquisition of Thinketron Precision Equipment Company Limited ('TPE') based in Hong Kong and its subsidiaries Baoding Longer Precision Pump Co., Ltd ('Longer Pump') based in China and Langer Instruments Corporation ('LIC') based in the USA.

 

Longer Pump manufactures and markets peristaltic, syringe and gear pumps used in laboratory, medical and industrial applications. LIC is Longer Pump's distributor in the USA.

 

The initial cash consideration was RMB 237 million (£23.7 million) for the share capital of TPE. Deferred consideration of RMB 3 million (£0.3 million), which is adjustable RMB for RMB if the net tangible asset value (NTAV) is over/under a targeted amount, is payable upon agreement of the NTAV. The targeted NTAV includes approximately RMB 22.5 million (£2.25 million) of cash.

 

Unaudited accounts for the year ended 31 December 2012 show adjusted operating profit of RMB 23.5 million (£2.35 million). Audited accounts for the year ended 31 December 2011 show adjusted operating profit of RMB 18.2 million (£1.82 million).

 

Existing management of Longer Pump and LIC will remain in place and will continue to operate the business supported by new Board members appointed from within Halma China. The acquisition, which is expected to be immediately earnings enhancing, has been funded from Halma's cash and debt facilities.

 

Longer Pump will join Halma's Health & Analysis sector within the Fluid Technology sub-sector adding complementary high-value fluid handling products which are sold through a large sales network in China. Approximately 80% of Longer Pump's revenue is generated from China.

 

 

Andrew Williams, Halma's Chief Executive, commented:

 

"Longer Pump's alignment with Halma's growth drivers is strong. Sales of their products are driven by increasing demand for healthcare and healthcare research, as well as the urbanisation and industrialisation within China. Their significant local market knowledge and technical resources will help our Fluid Technology sub-sector accelerate growth in this important region.

 

There are also opportunities for Halma to contribute to the growth of Longer Pump, utilising both the network of regional hub offices which Halma has established within China and the worldwide reach of our Fluid Technology businesses."

 

 

 

 

For further information please contact:

 

Halma plc

Andrew Williams, Chief Executive

Kevin Thompson, Finance Director

 

 

 

+44 (0)1494 721111

MHP Communications

Rachel Hirst/Andrew Jaques

+44 (0)20 3128 8100

 

Notes

 

1.

Exchange rate used: RMB 10/£1.

 

2.

Longer Pump has been specialising in the manufacture of peristaltic pumps, syringe pumps, gear pumps and pump accessories for 15 years. It has significant IP and R&D capabilities with sales to a diverse, mainly non-OEM, customer base.

 

Peristaltic pumps provide reliable solutions for demanding fluid handling applications in the laboratory, industrial and OEM markets.

 

Growth prospects in their core geographic market of China for peristaltic pumps are strong. One industry forecast expects market growth of approximately 12% for the next several years, before increasing to over 20% in 2016.

 

3.

Halma buys successful businesses in safety, health and environmental markets and helps them grow further through investment targeted towards increasing innovation, management development and international expansion. In the past 10 years Halma has spent approximately £400m acquiring 30 businesses with deal sizes ranging from £70m down to below £1m. Although businesses have been acquired in all areas of our activity, the majority of recent acquisitions has been in the Health & Analysis Sector.

 

4.

This statement is not intended to constitute a profit forecast for the current financial period or for any future period. In addition, this statement should not be taken to mean that the earnings per share of Halma will necessarily match or exceed the historic reported earnings per share of Halma.

 

5.

A copy of this announcement, together with other information about Halma and its Fluid Technology businesses, may be viewed on our website: www.halma.com.

 

6.

Halma's next Interim Management Statement will be issued on 14 February 2013.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQBJMPTMBATMJJ
Date   Source Headline
28th May 20267:15 amRNSExecutive Board changes
13th Apr 20267:00 amRNSAcquisition
12th Mar 20267:00 amRNSTrading Update
13th Jan 20269:18 amRNSDirector/PDMR Shareholding
9th Jan 20261:26 pmRNSDirector/PDMR Shareholding
9th Jan 20267:00 amRNSAcquisition
5th Dec 20257:00 amRNSAcquisition
20th Nov 20257:00 amRNSHalf Year Results
1st Oct 20252:00 pmRNSDirector/PDMR Shareholding
26th Sep 202510:19 amRNSDirector/PDMR Shareholding
25th Sep 20257:00 amRNSTrading Update
26th Aug 20257:00 amRNSAcquisition
24th Jul 20252:15 pmRNSResult of AGM
30th Jun 202511:30 amRNSDirector/PDMR Shareholding
25th Jun 20258:30 amRNSAGM - Revised Form of Proxy
24th Jun 20259:20 amRNSDirector/PDMR Shareholding
20th Jun 20255:15 pmRNSAnnual Financial Report
18th Jun 20254:47 pmRNSDirector/PDMR Shareholding
12th Jun 20257:00 amRNSFull Year Results
16th May 20257:00 amRNSDirectorate Change
28th Mar 20251:10 pmRNSDirector/PDMR Shareholding
21st Mar 20252:00 pmRNSDirectorate Change
13th Mar 20257:00 amRNSTrading Update
28th Feb 20254:29 pmRNSDirector/PDMR Shareholding
14th Jan 20252:05 pmRNSDirector/PDMR Shareholding
8th Jan 20257:00 amRNSAppointment of Chief Financial Officer
28th Nov 202410:04 amRNSDirector/PDMR Shareholding
22nd Nov 20243:30 pmRNSDirector/PDMR Shareholding
22nd Nov 20243:26 pmRNSDirector/PDMR Shareholding
21st Nov 20247:00 amRNSHalf Year Results
18th Nov 20247:00 amRNSAcquisition
6th Nov 20242:34 pmRNSDirector Declaration
2nd Oct 20249:20 amRNSDirector/PDMR Shareholding
26th Sep 20247:00 amRNSTrading Update
24th Sep 20249:45 amRNSDirector/PDMR Shareholding
3rd Sep 20249:15 amRNSPDMR Shareholding
25th Jul 20241:51 pmRNSResult of AGM
24th Jul 20249:15 amRNSDirector/PDMR Shareholding
17th Jul 202412:46 pmRNSDirector Declaration
1st Jul 20249:51 amRNSDirector/PDMR Shareholding
27th Jun 20247:00 amRNSAcquisition
25th Jun 20243:00 pmRNSDirector/PDMR Shareholding
24th Jun 20245:26 pmRNSAnnual Financial Report
13th Jun 20247:00 amRNSFull Year Results
1st May 20247:00 amRNSAcquisition
19th Mar 20243:53 pmRNSDirector/PDMR Shareholding
14th Mar 20247:00 amRNSTrading Update
4th Mar 20247:00 amRNSAcquisition
21st Feb 20244:17 pmRNSDirector/PDMR Shareholding
30th Jan 20247:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.